ACORI RESEARCH REVIEW: DECEMBER 2023


The Importance of Teams in the Success of Community Clinical Research

Oncology Advanced Practice Providers (APPs) including Nurse Practitioners, Physician Assistants, Clinical Nurse Specialists and Pharmacists are highly trained health care providers that contribute significantly to quality cancer care. The number of APPs in clinical practice has grown significantly over the past 10 years. Recent estimates believe there are over 10,000 in practice across the country and over 90% of oncology practices employ APPs.1


Profile: Society for Clinical Research Sites

In 2012, Christine Pierre, a long-time nurse and industry leader in the clinical trial space, founded the Society for Clinical Research Sites (SCRS) after realizing that the research world lacked a unified voice for individual trial sites. This realization came in part from discussions with other industry leaders and in part from surveys identifying ongoing needs in the research community. Pierre and her team wanted to establish an organization that would serve 4 main purposes for research sites around the world—advocate, educate, connect, and mentor—with the overarching goal of providing support for greater site sustainability. Unlike a professional organization, which caters to individual members, SCRS is a trade association, meaning that it serves businesses that operate in a specific industry—in this case, clinical research sites in the world of health care. SCRS is the only trade organization that represents and speaks on behalf of clinical research sites across the globe.


Robert A. Winn Diversity in Clinical Trials: Design and Implementation of Clinical Trials Workshop

The Robert A. Winn Diversity in Clinical Trials: Design and Implementation of Clinical Trials Workshop was recently held from November 15th through 19th in La Jolla, California, in partnership with the American Association for Cancer Research, Bristol Myers Squibb Foundation, and Virginia Commonwealth University. This 5-day intensive workshop aimed to educate and prepare early-stage investigators on clinical trial design, implementation, and community engagement, all from the lens of increasing diversity in clinical trials.


Summary of ACCC Innovator Award Recipient(s) at the 40th NOC

Earlier this fall, ACCC held its 40th National Oncology Conference (NOC) in Austin, Texas, where the theme of "Reimagining Innovation" took shape in various sessions discussing workforce issues, services for value-based care, and how cancer programs can leverage technology to optimize services and operations. Several key questions were posed and addressed throughout the conference: "How can we better use technology to support our workforce?" "Where can we streamline processes and procedures to realize greater efficiencies?" "What service lines can we expand or add to improve the patient experience, bolster our recruitment efforts, and grow our marketplace share?"


Insurance Status Implications on Clinical Trial Coverage from State to State

Many factors can impact a patient’s decision to participate in a clinical trial, from psychosocial considerations, such as mistrust or fear of research, to practical concerns, including logistical hurdles and financial burdens. With standard of care treatments, insurance coverage is more predictable in that routine scans and other services related to the treatment are typically covered as long as they adhere to major guidelines or treatment algorithms. But with clinical trials, the costs of care associated with study participation may often be excluded from the policy’s coverage, meaning that trial patients could end up being stuck with costs they otherwise would not have. Studies have reported that 10% to 85% of eligible patients have declined trial participation due to the potential denial of insurance coverage.


Clinical Trial Navigators and How They Help Patients Navigate the System

Cancer research is vital to the development of safer and more effective treatments, but barriers to participation continue to exist that lead to low levels of accrual. It is estimated that less than 10% of adult patients with cancer participate in clinical research. Understanding and addressing these barriers continues to be a significant area of focus for the global research community.